Current Status of Prostate-Specific Antigen in the Radiotherapeutic Management of Prostatic Cancer.

Abstract

The current data involving the use of prostate-specific antigen (PSA) in the radiotherapeutic management of localized prostatic cancer is reviewed. Controversies and ongoing debate notwithstanding, a number of general conclusions have been made. (1) PSA as a screening test has increased prostate cancer detection rates and is recommended as part of routine… (More)